BioCentury
ARTICLE | Financial News

G1 Therapeutics raises $33M in B round

February 6, 2015 2:13 AM UTC

G1 Therapeutics Inc. (Research Triangle Park, N.C.) raised $33 million in a series B round led by new investors Eshelman Ventures and RA Capital Management. New investors Lumira Capital and Tavistock Life Sciences' Boxer Capital also participated, as did existing investors Hatteras Venture Partners; MedImmune Ventures; and Mountain Group Capital.

Next quarter, G1 plans to begin a Phase Ib/IIa trial of IV G1T28, a selective inhibitor of cyclin dependent kinase 4 ( CDK4) and CDK6, to treat small cell lung cancer. In 4Q15 the company expects to start a Phase Ib/IIa study of an oral formulation for an undisclosed indication. G1 is studying the IV version as a bone marrow chemoprotectant for patients with CDK4/6-independent tumors and the oral version as an antineoplastic agent for patients with CDK4/6-dependent tumors. ...